ArticleExperimental & molecular medicine2026
NRIP1 disrupts ERα signal in Sjögren's disease via AQP5 suppression and MYC-driven salivary dysfunction.
Article in Experimental & molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sjögren's disease (SjD) is marked by dysfunction of the salivary gland (SG) caused by epithelial cell death. However, the mechanism remains unclear. Here we discovered that NRIP1 was abnormally upregulated in SjD and formed a protein complex with estrogen receptor α (ERα) to inhibit saliva secretion and lead to epithelial cell death. NRIP1 interacted with ERα and altered the estradiol (E2)-ERα downstream signal in the SG epithelium. In the context of SjD, NRIP1-ERα suppressed aquaporin-5 (AQP5) expression and promoted MYC expression. The NRIP1-ERα complex bound to the estrogen response elements of the AQP5 promoter, leading to the downregulation of AQP5 expression and reduced SG secretion. Conversely, the NRIP1-ERα complex bound to the estrogen response elements of the MYC promoter, resulting in the upregulation of MYC expression. Furthermore, we demonstrated that elevated MYC levels promoted apoptosis and altered immune regulation and cell metabolism in SjD. Nrip1-knockout/ovariectomized mice did not develop the SjD phenotypes, confirming the role of NRIP1 in the pathophysiology of SjD. Molecular dynamic simulations revealed that NRIP1 competitively bound to ERα and masked the E2 binding site, providing structural insights into the disruption of hormonal signal. This study implicates NRIP1 as a potent diagnosis parameter and provides a putative target for SjD management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.